Application of poplatin in preparation of medicine for preventing and / or treating pulmonary fibrosis
By using salicylic acid as the active ingredient to intervene in the core pathways of pulmonary fibrosis, drugs in various dosage forms have been prepared, solving the problems of limited efficacy and numerous side effects of existing drugs, and achieving effective treatment and inhibition of pulmonary fibrosis.
Patent Information
- Application Number
- CN202610011982.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-06
- Publication Date
- 2026-02-17
AI Technical Summary
Existing drugs for treating pulmonary fibrosis have limited efficacy, numerous side effects, and cannot reverse the disease progression. Furthermore, existing drugs have a single mechanism of action and fail to cover the multi-stage and multi-target pathogenesis of pulmonary fibrosis.
Using salicylic acid as the active ingredient, drugs for the prevention and/or treatment of pulmonary fibrosis are prepared by intervening in the core pathways of pulmonary fibrosis. These drugs include various dosage forms such as injections, oral preparations, and local targeted drug delivery. Their anti-inflammatory, antioxidant, and other bioactivities are used to intervene in pathological processes such as fibroblast activation.
Sausage extract significantly reduces the degree of pulmonary fibrosis, inhibits the expression of related markers, and suppresses fibroblast activation, providing a novel and safe treatment option for pulmonary fibrosis.
Smart Images

Figure CN121534040A_ABST
Abstract
Citation Information
Patent Citations
Application of poplatin in preparation of medicine for delaying ovarian aging and / or repairing damaged ovarian and / or reconstructing ovarian function
CN118490676A
Application of monomer poplar bud flavin derived from clinical compound application traditional Chinese medicine in preparation of medicine for treating nerve injury diseases
CN121731282A
Combination of quercetin and pathenolide as Anti-inflammatory agents for use in the treatment of dermatitis
WO2024035864A1